InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
4
T+90 hit rate
71%
T+90 mean return
+5.6%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Greenleaf Peter, Director. Director active across 4 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 20 filings have been published. Split: 2 buys · 4 sells. Total volume traded: €981k. Activity tracked since 11 May 2021. The latest transaction was disclosed on 2 July 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations20 total
712 shares@ US$25.9954Common StockSEC:0001919246-26-000100:0
85 shares@ US$27.2733Common StockSEC:0001919246-26-000100:1
25,478 shares0Common StockSEC:0001919246-26-000043
25,478 shares0Common StockSEC:0001919246-26-000043:0
290,728 shares0Common StockSEC:0001600620-25-000024:0
126,981 shares@ US$5.6068.0% of flowCommon StockSEC:0001600620-24-000038:0
661,538 shares0Common StockSEC:0001600620-24-000017:0
33,047 shares@ US$8.7828.3% of flowCommon StockSEC:0001600620-24-000013:0
667,407 sharesCommon StockSEC:0001628280-23-006526:0
30,220 shares@ US$5.6046.0% of flowCommon StockSEC:0000899243-22-019780:0
105,034 shares0Common StockSEC:0001103021-22-000067:0
28,300 shares0Common StockSEC:0001628280-22-005123:0
10,246 shares0Common StockSEC:0001103021-22-000021:0
10,246 shares0Common StockSEC:0001103021-22-000021
35,000 shares0Common StockSEC:0001103021-21-000070:0
35,000 shares0Common StockSEC:0001103021-21-000070
25,452 shares@ US$4.4227.0% of flowCommon StockSEC:0001209191-21-040329
25,452 shares@ US$4.4227.0% of flowCommon StockSEC:0001209191-21-040329:0
2,133 shares@ US$10.150.0008% mcap50.0% of flowCommon StockSEC:0001628280-21-010022:0
Ideal exit: 5 Feb 2022 (T+270)
2,133 shares@ US$10.1550.0% of flowCommon StockSEC:0001628280-21-010022
Ideal exit: 5 Feb 2022 (T+270)
20 of 20 declarations
About Greenleaf Peter
Peter Greenleaf is a Director and Chief Executive Officer of Pelthos Therapeutics Inc., Aurinia Pharmaceuticals Inc., and ANTARES PHARMA, INC. He leads these companies with a focus on innovation and the development of new treatments.
